uniQure (QURE)
Market Price (9/30/2026): $25.26 | Market Cap: $1.7 BilSector: Health Care | Industry: Biotechnology
uniQure (QURE)
Market Price (9/30/2026): $25.26Market Cap: $1.7 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -29% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -190 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1017% Expensive valuation multiplesP/SPrice/Sales ratio is 139x Stock price has recently run up significantly6M Rtn6 month market price return is 166% Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -31% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 98% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -861%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -865% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 145% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14% High stock price volatilityVol 12M is 139% Key risksQURE key risks include [1] an uncertain regulatory pathway for its lead Huntington's disease therapy, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -29% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -190 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1017% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 139x |
| Stock price has recently run up significantly6M Rtn6 month market price return is 166% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -31% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 98% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -861%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -865% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 145% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14% |
| High stock price volatilityVol 12M is 139% |
| Key risksQURE key risks include [1] an uncertain regulatory pathway for its lead Huntington's disease therapy, Show more. |
Qualitative Assessment
AI Analysis | Feedback
uniQure (QURE) stock has lost about 15% since 5/31/2026 because of the following key factors:
1. Disappointing 48-month clinical trial data for AMT-130 in Huntington's disease.
On September 29, 2026, uniQure announced 48-month data from its Phase I/II study of AMT-130, its lead gene therapy candidate for Huntington's disease, showing a 44% slowing of disease progression in high-dose patients on the prespecified primary cUHDRS endpoint, which was not statistically significant. This outcome represented a decrease in treatment benefit compared to the 80% slowing of disease progression reported at 36 months, which had formed the basis for the Biologics License Application (BLA) submitted for accelerated approval on September 2, 2026. The mixed results led to a substantial drop in uniQure's stock price, plummeting over 35% on September 29, 2026.
2. Fiscal Q2 2026 earnings per share (EPS) miss.
uniQure reported its fiscal Q2 2026 financial results on July 29, 2026, disclosing a loss of $1.22 per share. This loss was approximately 50-72% wider than the consensus analyst estimates, which ranged from a loss of $0.71 to $0.81 per share. While the company's revenue of $5.84 million for the quarter exceeded some analysts' expectations by about 24%, the significant EPS miss, attributed primarily to foreign currency swings and warrant fair value losses, contributed to negative investor sentiment during the period.
Show more
uniQure (QURE) stock has lost about 15% since 5/31/2026 because of the following key factors:
1. Disappointing 48-month clinical trial data for AMT-130 in Huntington's disease.
On September 29, 2026, uniQure announced 48-month data from its Phase I/II study of AMT-130, its lead gene therapy candidate for Huntington's disease, showing a 44% slowing of disease progression in high-dose patients on the prespecified primary cUHDRS endpoint, which was not statistically significant. This outcome represented a decrease in treatment benefit compared to the 80% slowing of disease progression reported at 36 months, which had formed the basis for the Biologics License Application (BLA) submitted for accelerated approval on September 2, 2026. The mixed results led to a substantial drop in uniQure's stock price, plummeting over 35% on September 29, 2026.
2. Fiscal Q2 2026 earnings per share (EPS) miss.
uniQure reported its fiscal Q2 2026 financial results on July 29, 2026, disclosing a loss of $1.22 per share. This loss was approximately 50-72% wider than the consensus analyst estimates, which ranged from a loss of $0.71 to $0.81 per share. While the company's revenue of $5.84 million for the quarter exceeded some analysts' expectations by about 24%, the significant EPS miss, attributed primarily to foreign currency swings and warrant fair value losses, contributed to negative investor sentiment during the period.
3. Increased regulatory uncertainty for AMT-130.
Despite uniQure's submission of a Biologics License Application (BLA) for accelerated approval of AMT-130 for Huntington's disease in early September 2026, based on promising 36-month data, the subsequent release of less robust 48-month clinical data has heightened regulatory risk. The lack of statistical significance in the 48-month data, contrasting with the 36-month results previously accepted by the FDA as a basis for submission, introduced doubts about the durability of the treatment's effect and the certainty of future regulatory approval. This uncertainty was compounded by reports of law firms initiating investigations into potential securities law violations following the data announcement.
Show less
Stock Movement Drivers
Fundamental Drivers
The -14.1% change in QURE stock from 5/31/2026 to 9/29/2026 was primarily driven by a -12.1% change in the company's P/S Multiple.| (LTM values as of) | 5312026 | 9292026 | Change |
|---|---|---|---|
| Stock Price ($) | 28.53 | 24.51 | -14.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 18 | 19 | 3.2% |
| P/S Multiple | 98.9 | 87.0 | -12.1% |
| Shares Outstanding (Mil) | 63 | 66 | -5.3% |
| Cumulative Contribution | -14.1% |
Market Drivers
5/31/2026 to 9/29/2026| Return | Correlation | |
|---|---|---|
| QURE | -14.1% | |
| Market (SPY) | 1.3% | -12.6% |
| Sector (XLV) | 14.7% | -17.4% |
Fundamental Drivers
The 56.8% change in QURE stock from 2/28/2026 to 9/29/2026 was primarily driven by a 49.8% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9292026 | Change |
|---|---|---|---|
| Stock Price ($) | 15.63 | 24.51 | 56.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 16 | 19 | 18.5% |
| P/S Multiple | 58.1 | 87.0 | 49.8% |
| Shares Outstanding (Mil) | 59 | 66 | -11.7% |
| Cumulative Contribution | 56.8% |
Market Drivers
2/28/2026 to 9/29/2026| Return | Correlation | |
|---|---|---|
| QURE | 56.8% | |
| Market (SPY) | 12.0% | -0.1% |
| Sector (XLV) | 7.5% | -7.6% |
Fundamental Drivers
The 50.1% change in QURE stock from 8/31/2025 to 9/29/2026 was primarily driven by a 39.3% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9292026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.33 | 24.51 | 50.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14 | 19 | 30.2% |
| P/S Multiple | 62.4 | 87.0 | 39.3% |
| Shares Outstanding (Mil) | 55 | 66 | -17.3% |
| Cumulative Contribution | 50.1% |
Market Drivers
8/31/2025 to 9/29/2026| Return | Correlation | |
|---|---|---|
| QURE | 50.1% | |
| Market (SPY) | 19.8% | -0.7% |
| Sector (XLV) | 26.4% | -3.9% |
Fundamental Drivers
The 181.4% change in QURE stock from 8/31/2023 to 9/29/2026 was primarily driven by a 2245.4% change in the company's P/S Multiple.| (LTM values as of) | 8312023 | 9292026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.71 | 24.51 | 181.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 112 | 19 | -83.3% |
| P/S Multiple | 3.7 | 87.0 | 2245.4% |
| Shares Outstanding (Mil) | 48 | 66 | -28.1% |
| Cumulative Contribution | 181.4% |
Market Drivers
8/31/2023 to 9/29/2026| Return | Correlation | |
|---|---|---|
| QURE | 181.4% | |
| Market (SPY) | 76.1% | 8.6% |
| Sector (XLV) | 34.8% | 4.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| QURE Return | -43% | 9% | -70% | 161% | 36% | 63% | 8% |
| Peers Return | -26% | 17% | 4% | -19% | 27% | -17% | -23% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 105% |
Monthly Win Rates [3] | |||||||
| QURE Win Rate | 25% | 33% | 8% | 50% | 33% | 56% | |
| Peers Win Rate | 43% | 62% | 48% | 42% | 60% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| QURE Max Drawdown | -52% | -39% | -76% | -55% | -72% | -68% | |
| Peers Max Drawdown | -42% | -29% | -34% | -41% | -43% | -38% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BMRN, SRPT, IONS, VRTX, RGNX. See QURE Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/29/2026 (YTD)
How Low Can It Go
| Event | QURE | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -37.8% | -18.8% |
| % Gain to Breakeven | 60.8% | 23.1% |
| Time to Breakeven | 14 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -35.1% | -7.8% |
| % Gain to Breakeven | 54.0% | 8.5% |
| Time to Breakeven | 113 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -40.8% | -9.5% |
| % Gain to Breakeven | 68.9% | 10.5% |
| Time to Breakeven | 257 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -47.9% | -6.7% |
| % Gain to Breakeven | 92.1% | 7.1% |
| Time to Breakeven | 818 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -38.8% | -24.5% |
| % Gain to Breakeven | 63.5% | 32.4% |
| Time to Breakeven | 57 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -38.3% | -33.7% |
| % Gain to Breakeven | 62.2% | 50.9% |
| Time to Breakeven | 76 days | 140 days |
In The Past
uniQure's stock fell -37.8% during the 2025 US Tariff Shock. Such a loss loss requires a 60.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | QURE | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -37.8% | -18.8% |
| % Gain to Breakeven | 60.8% | 23.1% |
| Time to Breakeven | 14 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -35.1% | -7.8% |
| % Gain to Breakeven | 54.0% | 8.5% |
| Time to Breakeven | 113 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -40.8% | -9.5% |
| % Gain to Breakeven | 68.9% | 10.5% |
| Time to Breakeven | 257 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -47.9% | -6.7% |
| % Gain to Breakeven | 92.1% | 7.1% |
| Time to Breakeven | 818 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -38.8% | -24.5% |
| % Gain to Breakeven | 63.5% | 32.4% |
| Time to Breakeven | 57 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -38.3% | -33.7% |
| % Gain to Breakeven | 62.2% | 50.9% |
| Time to Breakeven | 76 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -31.1% | -19.2% |
| % Gain to Breakeven | 45.1% | 23.8% |
| Time to Breakeven | 78 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -42.0% | -3.7% |
| % Gain to Breakeven | 72.4% | 3.9% |
| Time to Breakeven | 76 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -60.7% | -12.2% |
| % Gain to Breakeven | 154.2% | 13.9% |
| Time to Breakeven | 755 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -20.8% | -6.8% |
| % Gain to Breakeven | 26.2% | 7.3% |
| Time to Breakeven | 27 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -39.1% | -0.2% |
| % Gain to Breakeven | 64.2% | 0.2% |
| Time to Breakeven | 219 days | 1 days |
In The Past
uniQure's stock fell -37.8% during the 2025 US Tariff Shock. Such a loss loss requires a 60.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About uniQure (QURE)
uniQure N.V. (QURE) is a biotechnology company specializing in the development of gene therapies. Based in the Netherlands, the company's core mission is to create innovative treatments for individuals affected by severe genetic and other debilitating diseases. Its foundational approach involves leveraging gene therapy technology to address the underlying causes of these conditions, aiming to provide long-term therapeutic solutions.
The company's most advanced product candidate is Etranacogene dezaparvovec (AMT-061), currently in a pivotal Phase III clinical trial for the treatment of hemophilia B, a genetic bleeding disorder. Beyond this lead program, uniQure boasts a robust pipeline of gene therapies targeting other serious neurological conditions. Notable programs include AMT-130, in Phase I/II development for Huntington's disease, and early-stage candidates like AMT-210 for Parkinson's disease, AMT-260 for temporal lobe epilepsy, and AMT-240 for autosomal dominant Alzheimer's disease, among others.
uniQure's primary customers are patients living with rare and devastating genetic or neurological disorders for which current treatment options may be limited or insufficient. By focusing on conditions such as hemophilia B, Huntington's, Parkinson's, and certain forms of epilepsy and Alzheimer's, uniQure aims to serve critical unmet medical needs within the global pharmaceutical and biotechnology market, specifically within the specialty field of advanced gene therapies.
AI Analysis | Feedback
Analogy 1: Imagine **Moderna**, but instead of mRNA technology, uniQure focuses on developing groundbreaking gene therapies for genetic diseases.
Analogy 2: A **Vertex Pharmaceuticals** dedicated to creating gene therapies for severe genetic conditions like hemophilia and Huntington's disease.
AI Analysis | Feedback
- Etranacogene dezaparvovec (AMT-061): A gene therapy in Phase III clinical trial for the treatment of hemophilia B.
- AMT-130: A gene therapy in Phase I/II clinical study for the treatment of Huntington's disease.
- AMT-060: A gene therapy in Phase I/II clinical trial for the treatment of hemophilia B.
- AMT-210: A product candidate for the treatment of Parkinson's disease.
- AMT-260: A product candidate for the treatment of temporal lobe epilepsy.
- AMT-240: A preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease.
- AMT-161: A product candidate for the treatment of amyotrophic lateral sclerosis.
AI Analysis | Feedback
AI Analysis | Feedback
- Bristol Myers Squibb Company (BMY)
- Catalent, Inc. (CTLT)
- Lonza Group Ltd (LONN)
AI Analysis | Feedback
Matt Kapusta, Chief Executive Officer
Matt Kapusta has served as Chief Executive Officer of uniQure since December 2016 and is also an Executive Director on the Board. He previously held the role of Chief Financial Officer for uniQure from January 2015 until June 2021. Prior to joining uniQure, Mr. Kapusta held executive positions at AngioDynamics from 2011 to 2015 and Smith & Nephew from 2009 to 2011. His career also includes more than a decade of investment banking experience focused on emerging life-sciences companies, including serving as Managing Director, Healthcare Investment Banking at Collins Stewart, and various roles at Wells Fargo Securities, Robertson Stephens, and PaineWebber.
Christian Klemt, Chief Financial Officer
Christian Klemt was appointed Chief Financial Officer of uniQure in June 2021. Prior to this role, he served as uniQure's Chief Accounting Officer from August 2017 to June 2021. Mr. Klemt also continues to serve as the General Manager of uniQure's Amsterdam site.
Walid Abi-Saab, M.D., Chief Medical Officer
Walid Abi-Saab joined uniQure as Chief Medical Officer in June 2023. In this role, he is responsible for leading clinical research and development, regulatory affairs, medical affairs, and program management. Before uniQure, Dr. Abi-Saab served as Chief Medical Officer at Galapagos from 2017 through 2022, where he expanded the company's development organization and led the successful completion of Phase 3 studies for filgotinib. He has also held leadership positions at companies such as Novartis, Abbott Laboratories, Pfizer, and served as Group Vice President, Global Clinical Development at Shire.
Richard Porter, Ph.D., Chief Business and Scientific Officer
Richard Porter assumed responsibilities for research, non-clinical, and vector development in his role as Chief Business and Scientific Officer following a strategic reorganization in October 2023. He also continues to oversee business development and product planning. Dr. Porter joined uniQure in June 2021 through the acquisition of Corlieve Therapeutics, where he was the founder and Chief Executive Officer. He possesses over 25 years of neuroscience leadership experience in the biopharma industry.
Kylie O'Keefe, Chief Customer and Strategy Officer
Kylie O'Keefe was appointed Chief Customer and Strategy Officer in June 2025, where she is responsible for leading the development and execution of uniQure's global commercialization strategy for AMT-130, including all commercial functions and medical affairs. Prior to joining uniQure, Ms. O'Keefe served as Chief Commercial Officer at PTC Therapeutics, overseeing global commercial strategy, operations, and portfolio management for multiple rare neurology and metabolic commercial products across more than 50 countries. Her experience includes leading several strategically significant commercial launches and supporting corporate strategy and pipeline development for both small molecules and gene therapies.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
uniQure N.V. (symbol: QURE) operates in the gene therapy space, developing treatments for genetic and other devastating diseases. The addressable markets for their main products are as follows:
Etranacogene dezaparvovec (HEMGENIX) for Hemophilia B
HEMGENIX (etranacogene dezaparvovec) is uniQure's approved gene therapy for hemophilia B. The global market for hemophilia B gene therapy was valued at approximately USD 0.51 billion in 2023 and is projected to reach USD 3.43 billion by 2032, growing at a compound annual growth rate (CAGR) of roughly 23.60% between 2024 and 2032. The broader global hemophilia B market was valued at US$ 2,956.0 million in 2024 and is estimated to grow to US$ 4,362.0 million by 2030. In the United States, the hemophilia B market size was approximately USD 2 billion in 2023.
AMT-130 for Huntington's Disease
Huntington's disease impacts approximately 75,000 people across the U.S., Europe, and the UK. The global Huntington's disease treatment market was valued at USD 1.2 billion in 2024 and is projected to reach USD 3.7 billion by 2034, exhibiting an 8.9% CAGR. Another estimate places the global market at USD 578.9 million in 2024, expected to reach USD 2,443 million by 2033 with a CAGR of 17.4% from 2025-2033. The North American market for Huntington's disease treatment held the leading regional position in 2024, with an estimated value of approximately USD 0.5 billion.
AMT-210 for Parkinson's Disease
uniQure announced in October 2023 its decision to discontinue the AMT-210 program for Parkinson's disease as part of a strategic reorganization. Therefore, there is no addressable market size for this specific product from uniQure's portfolio.
AI Analysis | Feedback
- Commercialization and Market Penetration of Hemgenix (etranacogene dezaparvovec): uniQure's approved gene therapy for hemophilia B, Hemgenix, is a current source of revenue, and its continued rollout and increasing adoption in the market are anticipated to contribute to revenue growth.
- Potential Regulatory Approval and Commercial Launch of AMT-130 for Huntington's Disease: Despite recent regulatory setbacks and the U.S. FDA recommending a Phase III sham-controlled study, AMT-130 remains a significant potential revenue driver. Analysts project substantial annual revenue if approved, with a potential commercial launch in 2027 or 2028.
- Expansion into International Markets: The company is actively engaging with regulatory authorities outside the U.S. for its pipeline assets, including AMT-130. This strategic focus on international markets presents an opportunity for geographical expansion and increased revenue from existing or newly approved products.
AI Analysis | Feedback
Share Issuance
- In 2025, uniQure received aggregate net proceeds of $404.2 million from follow-on public offerings, which included the issuance of 11.8 million ordinary shares and pre-funded warrants to purchase 0.5 million ordinary shares.
- An underwritten public offering in September 2025 generated approximately $345 million in gross proceeds from the sale of 6,736,841 ordinary shares and 526,316 pre-funded warrants.
- Net proceeds of $80.5 million were raised in January and February 2025 through a follow-on offering.
Inbound Investments
- uniQure refinanced its existing $50 million debt in the third quarter of 2025, extending the term to October 2030 and reducing its cost of capital.
- An additional term loan tranche of $100 million is available, subject to a pre-defined regulatory milestone for AMT-130, with a third tranche of $25 million also available upon lender approval.
- The company's cash and investments grew to $622.5 million as of December 31, 2025, primarily due to proceeds from public offerings, up from $367.5 million at the end of 2024.
Capital Expenditures
- Research and development expenses totaled $140.7 million in 2025, a decrease from $143.8 million in 2024.
- Selling, general and administrative expenses were $65.5 million in 2025, increasing from $52.7 million in 2024, partly due to $6.5 million incurred for the planned commercialization of AMT-130 in the United States.
- In the third quarter of 2025, direct research and development expenses increased by $10.1 million, including $6.6 million related to the preparation for the Biologics License Application submission for AMT-130.
Peer Outperformance in Biotechnology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 7.3% | 44.8% | 91.5% | CAH 400% · MCK 344% · COR 172% |
| Health Care Services | 20 | 18.5% | 36.2% | 5.7% | HIMS 281% · RDNT 141% · DGX 76% |
| Managed Health Care | 8 | 32.0% | -7.4% | 4.7% | OSCR 71% · HQY 35% · ELV 13% |
| Health Care Facilities | 24 | 2.4% | 7.6% | -3.3% | THC 288% · NHC 263% · ENSG 137% |
| Health Care Equipment | 50 | -2.4% | -1.0% | -15.1% | POCI 10575% · UFPT 382% · GKOS 229% |
| Pharmaceuticals | 62 | -7.7% | -0.5% | -28.8% | LQDA 2461% · INDV 1157% · ETON 1074% |
| Health Care Supplies | 12 | 27.5% | -7.6% | -37.1% | LNTH 288% · HAE 50% · MMSI 22% |
| Life Sciences Tools & Services | 109 | -1.0% | -16.8% | -66.5% | SNWV 1835% · NTRA 272% · MEDP 229% |
| Health Care Technology | 21 | -33.1% | -53.9% | -76.9% | SPOK 69% · HSTM 6% · VEEV -3% |
| Biotechnology ← | 363 | -10.5% | -24.8% | -78.3% | CELZ 1279% · DNTH 1097% · ELVN 1040% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| uniQure Stock Pre-Market (+51%): FDA Clarifies Trial Path, Igniting Squeeze | 03/07/2026 | |
| Would You Still Hold uniQure Stock If It Fell Another 30%? | 10/17/2025 | |
| uniQure (QURE) Operating Cash Flow Comparison | 09/25/2025 | |
| uniQure (QURE) Operating Income Comparison | 09/25/2025 | |
| uniQure (QURE) Net Income Comparison | 09/25/2025 | |
| uniQure (QURE) Debt Comparison | 09/25/2025 | |
| uniQure (QURE) Tax Expense Comparison | 09/25/2025 | |
| uniQure (QURE) Revenue Comparison | 09/25/2025 | |
| uniQure (QURE) EBITDA Comparison | 09/25/2025 | |
| QURE Dip Buy Analysis | 07/10/2025 | |
| ARTICLES | ||
| Market Movers | Winners: IOVA, ITG, DNA | Losers: QURE, FICO, CLPT | 09/30/2026 | |
| Market Movers | Winners: QURE, FTHM, ELTX | Losers: ADTX, LILA, GDC | 06/18/2026 | |
| Market Movers | Winners: ADTX, CJET, ABP | Losers: DD, QURE, ZOOZ | 11/04/2025 | |
| UniQure’s Rally Is Just Getting Started | 09/25/2025 | |
| Market Movers | Winners: MNDR, QURE, SHFS | Losers: WOK, JZXN, INHD | 09/25/2025 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 35.56 |
| Mkt Cap | 4.7 |
| Rev LTM | 1,424 |
| Op Inc LTM | -113 |
| FCF LTM | -43 |
| FCF 3Y Avg | -165 |
| CFO LTM | -25 |
| CFO 3Y Avg | -161 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.7% |
| Rev Chg 3Y Avg | 13.8% |
| Rev Chg Q | 11.7% |
| QoQ Delta Rev Chg LTM | 3.1% |
| Op Inc Chg LTM | -48.3% |
| Op Inc Chg 3Y Avg | 3.1% |
| Op Mgn LTM | -35.6% |
| Op Mgn 3Y Avg | -23.6% |
| QoQ Delta Op Mgn LTM | -1.7% |
| CFO/Rev LTM | -25.6% |
| CFO/Rev 3Y Avg | -26.1% |
| FCF/Rev LTM | -30.6% |
| FCF/Rev 3Y Avg | -31.8% |
Price Behavior
| Market Price | $24.51 | |
| Market Cap ($ Bil) | 1.6 | |
| First Trading Date | 02/05/2014 | |
| Distance from 52W High | -65.3% | |
| 50 Days | 200 Days | |
| DMA Price | $44.17 | $29.62 |
| DMA Trend | up | up |
| Distance from DMA | -44.5% | -17.3% |
| 3M | 1YR | |
| Volatility | 90.5% | 143.9% |
| Downside Capture | 449.42 | 120.37 |
| Upside Capture | 52.67 | -3.54 |
| Correlation (SPY) | 9.7% | 3.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.63 | 0.34 | -2.23 | -0.21 | -0.30 | 1.09 |
| Up Beta | -1.24 | 1.45 | 1.10 | 2.71 | 3.25 | 1.39 |
| Down Beta | 1.77 | -2.84 | -6.07 | -3.83 | 0.18 | 1.60 |
| Up Capture | 212% | 92% | -7% | 140% | -2% | 174% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 10 | 20 | 28 | 61 | 116 | 346 |
| Down Capture | 56% | 45% | -410% | -216% | -423% | 89% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 11 | 22 | 35 | 65 | 134 | 394 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QURE | |
|---|---|---|---|---|
| QURE | -55.0% | 143.9% | 0.13 | - |
| Sector ETF (XLV) | 27.7% | 16.0% | 1.33 | -2.4% |
| Equity (SPY) | 16.5% | 13.0% | 0.90 | 4.2% |
| Gold (GLD) | 10.5% | 29.6% | 0.34 | 1.4% |
| Commodities (DBC) | 40.5% | 20.8% | 1.52 | -0.7% |
| Real Estate (VNQ) | 3.2% | 13.6% | -0.02 | -11.7% |
| Bitcoin (BTCUSD) | -24.6% | 44.7% | -0.50 | 0.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QURE | |
|---|---|---|---|---|
| QURE | -8.5% | 158.9% | 0.44 | - |
| Sector ETF (XLV) | 7.0% | 15.2% | 0.27 | 9.0% |
| Equity (SPY) | 13.5% | 17.2% | 0.60 | 13.9% |
| Gold (GLD) | 18.2% | 18.9% | 0.78 | -0.6% |
| Commodities (DBC) | 10.6% | 19.6% | 0.42 | 0.6% |
| Real Estate (VNQ) | 0.9% | 18.9% | -0.06 | 6.7% |
| Bitcoin (BTCUSD) | 15.3% | 52.4% | 0.46 | 8.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QURE | |
|---|---|---|---|---|
| QURE | 12.2% | 122.8% | 0.50 | - |
| Sector ETF (XLV) | 10.9% | 16.7% | 0.53 | 14.2% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 17.0% |
| Gold (GLD) | 11.8% | 16.4% | 0.59 | 0.5% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | 3.4% |
| Real Estate (VNQ) | 4.6% | 20.7% | 0.18 | 9.1% |
| Bitcoin (BTCUSD) | 63.5% | 66.2% | 1.03 | 7.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/29/2026 | 9.3% | 19.1% | 39.0% |
| 5/5/2026 | 2.3% | 33.7% | 44.5% |
| 3/2/2026 | -32.8% | -8.7% | -5.8% |
| 11/10/2025 | -5.9% | 7.5% | -27.5% |
| 7/29/2025 | -8.7% | -8.1% | 5.4% |
| 5/9/2025 | 4.4% | 8.2% | 38.0% |
| 2/27/2025 | 3.4% | 3.6% | 12.5% |
| 11/5/2024 | 9.0% | 37.8% | 13.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 11 | 13 |
| # Negative | 10 | 13 | 11 |
| Median Positive | 3.5% | 7.8% | 15.0% |
| Median Negative | -4.3% | -8.5% | -17.8% |
| Max Positive | 12.7% | 37.8% | 44.5% |
| Max Negative | -32.8% | -25.3% | -27.5% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/29/2026 | 9.3% | 19.1% | 39.0% |
| 5/5/2026 | 2.3% | 33.7% | 44.5% |
| 3/2/2026 | -32.8% | -8.7% | -5.8% |
| 11/10/2025 | -5.9% | 7.5% | -27.5% |
| 7/29/2025 | -8.7% | -8.1% | 5.4% |
| 5/9/2025 | 4.4% | 8.2% | 38.0% |
| 2/27/2025 | 3.4% | 3.6% | 12.5% |
| 11/5/2024 | 9.0% | 37.8% | 13.1% |
| 8/1/2024 | -2.3% | -7.0% | -18.8% |
| 5/7/2024 | 2.1% | 3.4% | 15.0% |
| 2/28/2024 | -0.9% | -25.3% | -19.9% |
| 11/7/2023 | 12.7% | -1.8% | 15.4% |
| 8/1/2023 | -5.3% | -19.2% | -17.8% |
| 5/9/2023 | 0.8% | 0.2% | -5.6% |
| 2/27/2023 | -0.2% | -0.7% | -4.4% |
| 11/2/2022 | -2.7% | -8.3% | 28.8% |
| 8/8/2022 | -27.0% | -20.2% | -23.6% |
| 5/2/2022 | 1.0% | -14.5% | -10.2% |
| 2/28/2022 | 2.9% | -8.5% | 4.8% |
| 10/25/2021 | -3.3% | 8.0% | -4.2% |
| 7/27/2021 | 4.5% | 7.2% | 4.2% |
| 5/10/2021 | 1.7% | -1.7% | 13.3% |
| 3/1/2021 | 3.7% | -11.5% | -17.8% |
| 10/28/2020 | 3.6% | 7.8% | 21.6% |
| SUMMARY STATS | |||
| # Positive | 14 | 11 | 13 |
| # Negative | 10 | 13 | 11 |
| Median Positive | 3.5% | 7.8% | 15.0% |
| Median Negative | -4.3% | -8.5% | -17.8% |
| Max Positive | 12.7% | 37.8% | 44.5% |
| Max Negative | -32.8% | -25.3% | -27.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/29/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/02/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 07/29/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/05/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/01/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/29/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/02/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 07/29/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/05/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/01/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/02/2022 | 10-Q |
| 12/31/2021 | 02/25/2022 | 10-K |
| 09/30/2021 | 10/25/2021 | 10-Q |
| 06/30/2021 | 07/26/2021 | 10-Q |
| 03/31/2021 | 05/10/2021 | 10-Q |
| 12/31/2020 | 03/01/2021 | 10-K |
| 09/30/2020 | 10/27/2020 | 10-Q |
| 06/30/2020 | 07/30/2020 | 10-Q |
| 03/31/2020 | 04/29/2020 | 10-Q |
| 12/31/2019 | 03/02/2020 | 10-K |
| 09/30/2019 | 10/28/2019 | 10-Q |
Recent Forward Guidance
Updated 9/28/2026Latest: Q2 2026 Earnings Reported 7/29/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2026 BLA Submission for AMT-130 | Reported | |||||||
| Q3 2026 Topline four-year data from the Phase I/II study of AMT-130 | Reported | |||||||
| Q3 2026 Complete enrollment in the second dose cohort in the Phase I/IIa study for MTLE | Reported | |||||||
| Q1 2027 Updated results from the Phase I/IIa study | Reported | |||||||
Prior: Q1 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2029 Cash Runway | Reported | 2029.5 | ||||||
Q4 2025 Earnings Reported 3/2/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2029 Cash Runway | Reported | |||||||
Q3 2025 Earnings Reported 11/10/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Patient Dosing Completion | Reported | 2025 | ||||||
| 2029 Cash Runway | Reported | 2029 | Raised | Guidance: 2027 for 2027 | ||||
Insider Activity
Updated 7/7/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kapusta, Matthew C | CEO, Managing Director | Direct | Sell | 7072026 | 45.16 | 21,082 | 952,051 | 23,447,999 | Form |
| 2 | Abi-Saab, Walid | Chief Medical Officer | Direct | Sell | 7022026 | 46.42 | 30,000 | 1,392,600 | 6,881,069 | Form |
| 3 | Kaye, Jack | Direct | Sell | 7022026 | 46.44 | 21,167 | 983,030 | 1,207,297 | Form | |
| 4 | Abi-Saab, Walid | Chief Medical Officer | Direct | Sell | 6302026 | 46.86 | 1,434 | 67,197 | 7,883,492 | Form |
| 5 | Kapusta, Matthew C | CEO, Managing Director | Direct | Sell | 6262026 | 50.02 | 28,716 | 1,436,374 | 25,971,735 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kapusta, Matthew C | CEO, Managing Director | Direct | Sell | 7072026 | 45.16 | 21,082 | 952,051 | 23,447,999 | Form |
| 2 | Abi-Saab, Walid | Chief Medical Officer | Direct | Sell | 7022026 | 46.42 | 30,000 | 1,392,600 | 6,881,069 | Form |
| 3 | Kaye, Jack | Direct | Sell | 7022026 | 46.44 | 21,167 | 983,030 | 1,207,297 | Form | |
| 4 | Abi-Saab, Walid | Chief Medical Officer | Direct | Sell | 6302026 | 46.86 | 1,434 | 67,197 | 7,883,492 | Form |
| 5 | Kapusta, Matthew C | CEO, Managing Director | Direct | Sell | 6262026 | 50.02 | 28,716 | 1,436,374 | 25,971,735 | Form |
| 6 | Kapusta, Matthew C | CEO, Managing Director | Direct | Sell | 6262026 | 50.00 | 6,696 | 334,800 | 25,961,350 | Form |
| 7 | Kapusta, Matthew C | CEO, Managing Director | Direct | Sell | 6222026 | 50.00 | 41,671 | 2,083,550 | 26,089,750 | Form |
| 8 | Kapusta, Matthew C | CEO, Managing Director | Direct | Sell | 6222026 | 44.32 | 164,429 | 7,288,062 | 24,768,391 | Form |
| 9 | Balachandran, Madhavan | Direct | Sell | 6222026 | 45.06 | 11,685 | 526,485 | 1,948,872 | Form | |
| 10 | Kaye, Jack | Direct | Sell | 6222026 | 42.57 | 5,295 | 225,408 | 1,106,650 | Form | |
| 11 | Balachandran, Madhavan | Direct | Sell | 6172026 | 27.85 | 10,000 | 278,500 | 1,204,624 | Form | |
| 12 | Potts, Jeannette | Chief Legal Officer | Direct | Sell | 6172026 | 27.67 | 5,237 | 144,908 | 3,686,917 | Form |
| 13 | Meek, David D | Direct | Sell | 6122026 | 27.06 | 1,993 | 53,931 | 1,075,554 | Form | |
| 14 | Gut, Robert | Direct | Sell | 6122026 | 27.06 | 2,726 | 73,766 | 872,929 | Form | |
| 15 | O'Keefe, Kylie | Chief Customer & Strat Officer | Direct | Sell | 6122026 | 27.06 | 15,936 | 431,228 | 2,945,860 | Form |
| 16 | Springhorn, Jeremy P | Direct | Sell | 6122026 | 27.06 | 1,993 | 53,931 | 1,170,372 | Form | |
| 17 | Post, Leonard E | Direct | Sell | 6122026 | 27.06 | 1,993 | 53,931 | 960,468 | Form | |
| 18 | Kaye, Jack | Direct | Sell | 6122026 | 27.06 | 1,993 | 53,931 | 703,452 | Form | |
| 19 | Jacques, Rachelle Suzanne | Direct | Sell | 6122026 | 27.06 | 1,993 | 53,931 | 917,415 | Form | |
| 20 | Balachandran, Madhavan | Direct | Sell | 6122026 | 27.06 | 1,993 | 53,931 | 1,170,453 | Form | |
| 21 | Gut, Robert | Direct | Sell | 6122026 | 26.05 | 7,552 | 196,720 | 714,647 | Form | |
| 22 | Kaye, Jack | Direct | Sell | 6052026 | 30.01 | 2,645 | 79,376 | 613,374 | Form | |
| 23 | Abi-Saab, Walid | Chief Medical Officer | Direct | Sell | 5122026 | 25.06 | 45,000 | 1,127,500 | 4,251,151 | Form |
| 24 | Kapusta, Matthew C | CEO, Managing Director | Direct | Sell | 3062026 | 9.06 | 14,581 | 132,104 | 5,985,561 | Form |
| 25 | Abi-Saab, Walid | Chief Medical Officer | Direct | Sell | 3062026 | 9.06 | 808 | 7,320 | 1,718,401 | Form |
| 26 | Potts, Jeannette | Chief Legal Officer | Direct | Sell | 3062026 | 9.06 | 3,412 | 30,913 | 1,254,656 | Form |
| 27 | Klemt, Christian | Chief Financial Officer | Direct | Sell | 3062026 | 9.06 | 12,000 | 108,720 | 2,052,824 | Form |
| 28 | Kapusta, Matthew C | CEO, Managing Director | Direct | Sell | 3042026 | 9.95 | 34,437 | 342,648 | 6,016,158 | Form |
| 29 | Klemt, Christian | Chief Financial Officer | Direct | Sell | 3042026 | 9.95 | 12,532 | 124,693 | 1,979,861 | Form |
| 30 | Potts, Jeannette | Chief Legal Officer | Direct | Sell | 3042026 | 9.95 | 8,578 | 85,351 | 1,059,625 | Form |
| 31 | Abi-Saab, Walid | Chief Medical Officer | Direct | Sell | 3042026 | 9.95 | 1,660 | 16,517 | 1,480,331 | Form |
| 32 | Kapusta, Matthew C | CEO, Managing Director | Direct | Sell | 2272026 | 23.86 | 12,378 | 295,339 | 15,248,353 | Form |
| 33 | Klemt, Christian | Chief Financial Officer | Direct | Sell | 2272026 | 23.86 | 6,217 | 148,338 | 5,046,700 | Form |
| 34 | Kaye, Jack | Direct | Sell | 1122026 | 27.28 | 6,390 | 174,319 | 557,576 | Form | |
| 35 | Gut, Robert | Direct | Sell | 11102025 | 27.26 | 31,434 | 856,881 | 1,094,340 | Form | |
| 36 | Kaye, Jack | Direct | Sell | 11062025 | 30.34 | 38,810 | 1,177,517 | 620,131 | Form | |
| 37 | Klemt, Christian | Chief Financial Officer | Direct | Sell | 9262025 | 55.00 | 15,000 | 825,000 | 11,975,150 | Form |
| 38 | Kapusta, Matthew C | CEO, Managing Director | Direct | Sell | 9262025 | 41.46 | 226,316 | 9,382,473 | 27,007,588 | Form |
| 39 | Klemt, Christian | Chief Financial Officer | Direct | Sell | 9262025 | 40.04 | 3,000 | 120,120 | 8,717,909 | Form |
| 40 | Abi-Saab, Walid | Chief Medical Officer | Direct | Sell | 7012025 | 13.92 | 1,466 | 20,407 | 2,094,083 | Form |
Investor Activity (13F)
Updated Sep 30, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Whitefort Capital Management, LP | $10.8 Mil | 3.3% | 19 | ADD +43.3% | 13F |
| MPM Bioimpact LLC | $22.4 Mil | 1.7% | 41 | Hold | 13F |
| Catalio Capital Management, LP | $8.0 Mil | 1.7% | 41 | ADD +70.3% | 13F |
| Mak Capital One LLC | $7.2 Mil | 1.2% | 21 | New | 13F |
| First Turn Management, LLC | $10.1 Mil | 1.1% | 33 | ADD +91.4% | 13F |
| Two Seas Capital LP | $21.3 Mil | 1.0% | 35 | New | 13F |
| Avoro Capital Advisors LLC | $97.4 Mil | 1.0% | 30 | Hold | 13F |
| Voss Capital, LP | $9.9 Mil | 0.6% | 39 | ADD +188.1% | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Two Seas Capital LP | $21.3 Mil | 1.0% | 35 | New | 13F |
| Mak Capital One LLC | $7.2 Mil | 1.2% | 21 | New | 13F |
| Voss Capital, LP | $9.9 Mil | 0.6% | 39 | ADD +188.1% | 13F |
| First Turn Management, LLC | $10.1 Mil | 1.1% | 33 | ADD +91.4% | 13F |
| Catalio Capital Management, LP | $8.0 Mil | 1.7% | 41 | ADD +70.3% | 13F |
| Whitefort Capital Management, LP | $10.8 Mil | 3.3% | 19 | ADD +43.3% | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | $97.4 Mil | 1.0% | 30 | Hold | 13F |
| MPM Bioimpact LLC | $22.4 Mil | 1.7% | 41 | Hold | 13F |
| Two Seas Capital LP | $21.3 Mil | 1.0% | 35 | New | 13F |
| Whitefort Capital Management, LP | $10.8 Mil | 3.3% | 19 | ADD +43.3% | 13F |
| First Turn Management, LLC | $10.1 Mil | 1.1% | 33 | ADD +91.4% | 13F |
| Voss Capital, LP | $9.9 Mil | 0.6% | 39 | ADD +188.1% | 13F |
| Catalio Capital Management, LP | $8.0 Mil | 1.7% | 41 | ADD +70.3% | 13F |
| Mak Capital One LLC | $7.2 Mil | 1.2% | 21 | New | 13F |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.